Logo image of ESPR

ESPERION THERAPEUTICS INC (ESPR) Stock Fundamental Analysis

NASDAQ:ESPR - Nasdaq - US29664W1053 - Common Stock - Currency: USD

1.41  -0.06 (-4.08%)

After market: 1.41 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ESPR. ESPR was compared to 194 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of ESPR have multiple concerns. While showing a medium growth rate, ESPR is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ESPR had negative earnings in the past year.
In the past year ESPR has reported a negative cash flow from operations.
In the past 5 years ESPR always reported negative net income.
In the past 5 years ESPR always reported negative operating cash flow.
ESPR Yearly Net Income VS EBIT VS OCF VS FCFESPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M

1.2 Ratios

With a Return On Assets value of -47.29%, ESPR perfoms like the industry average, outperforming 42.27% of the companies in the same industry.
Industry RankSector Rank
ROA -47.29%
ROE N/A
ROIC N/A
ROA(3y)-70.33%
ROA(5y)-64.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ESPR Yearly ROA, ROE, ROICESPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

1.3 Margins

Looking at the Gross Margin, with a value of 65.30%, ESPR is in the better half of the industry, outperforming 72.16% of the companies in the same industry.
ESPR's Gross Margin has been stable in the last couple of years.
ESPR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 65.3%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.04%
GM growth 5YN/A
ESPR Yearly Profit, Operating, Gross MarginsESPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

1

2. Health

2.1 Basic Checks

ESPR does not have a ROIC to compare to the WACC, probably because it is not profitable.
ESPR has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ESPR has been increased compared to 5 years ago.
Compared to 1 year ago, ESPR has an improved debt to assets ratio.
ESPR Yearly Shares OutstandingESPR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
ESPR Yearly Total Debt VS Total AssetsESPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

ESPR has an Altman-Z score of -6.29. This is a bad value and indicates that ESPR is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ESPR (-6.29) is worse than 64.95% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -6.29
ROIC/WACCN/A
WACC9.32%
ESPR Yearly LT Debt VS Equity VS FCFESPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M

2.3 Liquidity

A Current Ratio of 1.18 indicates that ESPR should not have too much problems paying its short term obligations.
ESPR has a Current ratio of 1.18. This is in the lower half of the industry: ESPR underperforms 79.38% of its industry peers.
A Quick Ratio of 0.81 indicates that ESPR may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.81, ESPR is doing worse than 82.47% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.18
Quick Ratio 0.81
ESPR Yearly Current Assets VS Current LiabilitesESPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 19.19% over the past year.
The Revenue has grown by 12.96% in the past year. This is quite good.
ESPR shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.50% yearly.
EPS 1Y (TTM)19.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-161.76%
Revenue 1Y (TTM)12.96%
Revenue growth 3Y61.84%
Revenue growth 5Y17.5%
Sales Q2Q%-52.81%

3.2 Future

The Earnings Per Share is expected to grow by 28.11% on average over the next years. This is a very strong growth
Based on estimates for the next years, ESPR will show a very strong growth in Revenue. The Revenue will grow by 26.48% on average per year.
EPS Next Y22.77%
EPS Next 2Y2.34%
EPS Next 3Y24.55%
EPS Next 5Y28.11%
Revenue Next Year5.49%
Revenue Next 2Y0.63%
Revenue Next 3Y11.63%
Revenue Next 5Y26.48%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ESPR Yearly Revenue VS EstimatesESPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
ESPR Yearly EPS VS EstimatesESPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -2 -4 -6 -8 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ESPR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ESPR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ESPR Price Earnings VS Forward Price EarningsESPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ESPR Per share dataESPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as ESPR's earnings are expected to grow with 24.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.34%
EPS Next 3Y24.55%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ESPR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ESPERION THERAPEUTICS INC

NASDAQ:ESPR (7/30/2025, 8:02:06 PM)

After market: 1.41 0 (0%)

1.41

-0.06 (-4.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-06 2025-05-06/bmo
Earnings (Next)08-05 2025-08-05/bmo
Inst Owners59.35%
Inst Owner Change0.23%
Ins Owners0.45%
Ins Owner Change11.36%
Market Cap279.46M
Analysts77.14
Price Target5.9 (318.44%)
Short Float %11.21%
Short Ratio4.91
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.74%
Min EPS beat(2)-32.97%
Max EPS beat(2)27.5%
EPS beat(4)2
Avg EPS beat(4)-16.23%
Min EPS beat(4)-75.67%
Max EPS beat(4)27.5%
EPS beat(8)5
Avg EPS beat(8)73.6%
EPS beat(12)7
Avg EPS beat(12)48.7%
EPS beat(16)11
Avg EPS beat(16)40.01%
Revenue beat(2)2
Avg Revenue beat(2)13.64%
Min Revenue beat(2)10.02%
Max Revenue beat(2)17.27%
Revenue beat(4)3
Avg Revenue beat(4)19.58%
Min Revenue beat(4)-1.37%
Max Revenue beat(4)52.41%
Revenue beat(8)7
Avg Revenue beat(8)20.63%
Revenue beat(12)8
Avg Revenue beat(12)12.82%
Revenue beat(16)11
Avg Revenue beat(16)11.95%
PT rev (1m)0%
PT rev (3m)-10.73%
EPS NQ rev (1m)-5.04%
EPS NQ rev (3m)-0.33%
EPS NY rev (1m)8.3%
EPS NY rev (3m)-889.49%
Revenue NQ rev (1m)1.79%
Revenue NQ rev (3m)6.22%
Revenue NY rev (1m)1.04%
Revenue NY rev (3m)-0.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.08
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.8
EYN/A
EPS(NY)-0.24
Fwd EYN/A
FCF(TTM)-0.51
FCFYN/A
OCF(TTM)-0.51
OCFYN/A
SpS1.31
BVpS-2.15
TBVpS-2.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -47.29%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 65.3%
FCFM N/A
ROA(3y)-70.33%
ROA(5y)-64.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.04%
GM growth 5YN/A
F-Score2
Asset Turnover0.8
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 274.16%
Cap/Sales 0.09%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.18
Quick Ratio 0.81
Altman-Z -6.29
F-Score2
WACC9.32%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-161.76%
EPS Next Y22.77%
EPS Next 2Y2.34%
EPS Next 3Y24.55%
EPS Next 5Y28.11%
Revenue 1Y (TTM)12.96%
Revenue growth 3Y61.84%
Revenue growth 5Y17.5%
Sales Q2Q%-52.81%
Revenue Next Year5.49%
Revenue Next 2Y0.63%
Revenue Next 3Y11.63%
Revenue Next 5Y26.48%
EBIT growth 1Y-15.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-122.85%
EBIT Next 3Y-16.98%
EBIT Next 5Y-5.8%
FCF growth 1Y47.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y47.37%
OCF growth 3YN/A
OCF growth 5YN/A